Updated:
BioAge Labs
BioAge Labs uses machine learning and a 50-year biobank to develop drugs for muscle atrophy and immune decline from human-validated aging targets.
BioAge Labs
BioAge Labs launched in 2015 after co-founders Kristen Fortney and Eric Morgen recognized that longitudinal human data — not model organisms — held the key to identifying aging's root causes. The company built its discovery engine atop a proprietary biobank of tens of thousands of blood samples collected over five decades, linked to detailed health records showing how individuals age at different rates. This resource, combined with machine learning, allows BioAge to pinpoint human-validated targets and then develop small-molecule drugs against them, a computationally defined process that distinguishes it from the broader longevity field. The company's pipeline focuses on two core indications: muscle atrophy and immune system decline. Its lead asset, BGE-175, inhibits prostaglandin D2 DP1 receptor signaling to reverse respiratory immune dysfunction, while BGE-117 targets a hypoxia-sensing pathway to treat age-related muscle loss. A pivotal Phase 2 trial readout for BGE-175 in hospitalized COVID-19 patients in 2023 demonstrated the platform's ability to rapidly translate computational discovery into clinical evidence. BioAge also maintains active programs in metabolic disease and neuroinflammation, with all targets sourced directly from its human aging atlas. Co-investors and partners have included Andreessen Horowitz, Kaiser Permanente, and Amgen, which provided access to genetic validation cohorts. BioAge operates from Richmond, California, with a team built around translational genomics, computational biology, and clinical development. In February 2024, the company closed a $170 million Series D round co-led by Sofinnova Investments and an undisclosed large pharma fund, bringing total venture backing to over $300 million (per Endpoints News, February 2024). The firm maintains a lean structure — no dedicated philanthropic arm — but keeps close ties with academic aging institutes such as the Buck Institute. Its clinical supply agreements with large pharmaceutical manufacturers provide manufacturing scale without building in-house infrastructure. BioAge's structural differentiator lies in its refusal to start from model organisms. Where conventional biotech screens for targets in worms or mice and struggles to translate hits to human disease, BioAge inverts that pipeline: it mines decades of real human aging data to find targets that already show a link to healthy longevity, then validates them in genetically enabled cohorts before ever synthesizing a molecule. This clinical-first, computation-driven architecture moves aging biology from hypothesis to validated target in one step, condensing the typical decade-plus discovery timeline into a process defined by existing human evidence.
General information
Firm type
Asset Manager
Year founded
2015
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Richmond
Corporate office
Richmond, CA, United States
Principals
Kristen Fortney
Co-Founder and CEO
Eric Morgen
Co-Founder and COO
Sector focus
Frequently asked questions
Who runs investment and R&D decisions at BioAge Labs?
Kristen Fortney, co-founder and CEO, leads both corporate strategy and scientific direction, with a PhD in computational biology from the University of Toronto. Co-founder Eric Morgen serves as COO, overseeing operations and the biobank infrastructure. Investment decisions are managed by the board, which includes representatives from Andreessen Horowitz and other major venture backers, while the scientific advisory board includes clinicians specializing in geroscience.
How does BioAge identify drug targets differently from other longevity companies?
BioAge relies on a proprietary human aging cohort — blood samples and health records from thousands of individuals tracked for over 50 years — rather than model organisms. The company deploys machine learning on this dataset to identify molecular signatures that predict healthy versus unhealthy aging trajectories. Targets that emerge from this human-first analysis enter genetic validation before the team develops small molecules against them, which is the reverse of typical pharma discovery pipelines.
Is BioAge a family office or a venture-backed operating company?
BioAge is a venture-backed biotechnology company, not a family office. It has raised over $300 million from institutional venture capital firms including Andreessen Horowitz, Sofinnova Investments, and Kaiser Permanente Ventures. The company uses this capital to fund internal drug discovery programs rather than managing external investor funds.
What clinical-stage programs does BioAge have?
BGE-175, a DP1 receptor inhibitor targeting immune decline, completed a Phase 2 trial in hospitalized COVID-19 patients in 2023, which helped validate the platform's ability to move from computational target to clinical readout. BGE-117, targeting muscle atrophy through a hypoxia-sensing pathway, is in early clinical development. The company also has preclinical programs in metabolic disease and neuroinflammation, all derived from its human aging atlas.
Does BioAge maintain philanthropic structures or a foundation?
BioAge does not operate a separate philanthropic foundation. The company channels its resources into for-profit drug development, though it collaborates with academic aging institutes such as the Buck Institute for Research on Aging. Its scientific founders publish openly in peer-reviewed geroscience journals, contributing to the broader longevity field through open science rather than structured philanthropy.
Which sectors does BioAge explicitly avoid?
The company focuses exclusively on age-related biological decline and does not pursue oncology, rare pediatric diseases, or non-aging central nervous system disorders. Its platform is tuned specifically to identify targets related to muscle wasting, immune senescence, and metabolic aging, intentionally steering clear of therapeutic areas where the underlying biology does not map to its longitudinal human data.
What is BioAge's known posture on co-investments alongside external pharma partners?
BioAge has partnered with Amgen on genetic validation studies and has taken strategic investment from large pharmaceutical funds, but the company remains independent and does not operate a co-investment vehicle for external limited partners. Its most recent Series D round included an undisclosed large pharma fund, suggesting ongoing structured collaboration without shared pipeline control.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: